Although PD-L1 is broadly expressed in normal and tumor cells [27], PD-L1 in tumor cells has upregulation in expression and site-specific aberrant glycan modifications that distinguish tumor cells from normal ones [28], and this decides its malignancy selectivity, making it an excellent choice for drug conjugation. The gene discussed is CD274; the disease is neoplasm.